Secular changes in NSAID use and invasive colorectal cancer incidence: An ecological study

Cancer Journal

Volumn 14, Issue 4, 2008, Pages 276-277

  Lamont, Elizabeth B ^a,b   Dias, Lauren E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; DATA ANALYSIS; DRUG UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK REDUCTION; CANCER REGISTRY; COLORECTAL TUMOR; HEALTH SURVEY; INCIDENCE; PILOT STUDY; RISK FACTOR; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; HEALTH SURVEYS; HUMANS; INCIDENCE; PILOT PROJECTS; POPULATION SURVEILLANCE; RISK FACTORS; SEER PROGRAM; UNITED STATES;

EID: 58149190492     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318182ee67     Document Type: Article

References (20)

1. Chu KC, Tarone RE, Chow WH, et al. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst. 1994;86:997-1006.
2. Schroy PC, Geller AC, Wood MC, et al. Utilization of colorectal cancer screening tests: a 1997 survey of Massachusetts internists. Preventative Med. 2001;33:381-391.
3. Ries LAG, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88:2398-2424.
4. Reese S, Owen P, Bender B, et al. Trends in screening for colorectal cancer-United States, 1997 and 1999. Morb Mort Wkly Rep. 2001;50: 162-166.
5. Anderson LM, May DS. Has the use of cervical, breast, and colorectal cancer screening increased in the United States? Am J Public Health. 1995;85:840-842.
6. Gabriel SE, Fehring RA. Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States, 1986-1990. J Clin Epidemiol. 1992;45:1041-1044.
7. Janne P, Mayer R. Chemoprevention of colorectal cancer. NEJM. 2000;342:1960-1968.
8. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene exrpression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183-1188.
9. Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res. 1998;58:4823-4826.
10. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal common cancer. N Engl J Med. 1991;325:1593-1596.
11. Smalley W, Ray WA, Daugherty J, et al. Use of nonsteroidal antiinflammatory drugs and incidence of colorectal cancer. Arch Intern Med. 1999;159:161-166.
12. Sturmer T, Glynn RJ, Lee I-M, et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' health Study. Ann Intern Med. 1998;128:713-720.
13. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294:914-923.
14. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008;134:21-28.
15. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294:914-923.
16. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008;134:21-28.
17. http://www.cdc.gov/nchs/about/major/ahcd/namcsdes.htm.
18. Ries LAG, Kosary CL, Hankey BF, et al. SEER cancer statistics review, 1973-1994. Bethesda, MD: National Cancer Institute 1997. NIH publication 97-2789.
19. Nattinger AB, McAuliffe TL, Schapira MM. Generalizability of the Surveillance, Epidemiology, and End Results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol. 1997;50:939-945.
20. http://seer.cancer.gov/seerstat/.